Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $32.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 79.37% from the company's current price.

A number of other research analysts have also recently issued reports on KURA. Wedbush reaffirmed an "outperform" rating and issued a $37.00 target price on shares of Kura Oncology in a report on Monday. StockNews.com cut Kura Oncology from a "hold" rating to a "sell" rating in a report on Thursday, August 22nd. Stifel Nicolaus downgraded Kura Oncology from a "buy" rating to a "hold" rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of "Moderate Buy" and a consensus price target of $28.83.

Kura Oncology Stock Performance

KURA stock traded up $0.32 during trading on Wednesday, hitting $17.84. The company had a trading volume of 1,446,633 shares, compared to its average volume of 592,695. The firm has a 50-day moving average price of $18.90 and a 200-day moving average price of $20.01. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.37 billion, a PE ratio of -8.00 and a beta of 0.86. Kura Oncology has a 1-year low of $8.17 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. Kura Oncology's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.53) EPS. On average, analysts expect that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Harbor Capital Advisors Inc. lifted its position in shares of Kura Oncology by 21.9% during the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company's stock worth $924,000 after purchasing an additional 8,505 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company's stock valued at $288,000 after purchasing an additional 5,788 shares in the last quarter. nVerses Capital LLC acquired a new position in Kura Oncology during the third quarter worth about $25,000. Quarry LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $196,000. Finally, Alethea Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company's stock worth $5,475,000 after acquiring an additional 6,300 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.